also suggested an increased risk of cholangiocarcinoma associated with the use of DPP-4 inhibitors and GLP-1 RAs, but the study involving GLP-1 RAs had a wide confidence interval, leading to some uncertainty in the conclusion ( Regarding the possible mechanisms of biliary diseases caused by these two types of drugs, existing studies have proposed multiple hypotheses
This article covers the FDA shortage-list context that opened the compounding pathway, the 2024 shortage resolution that narrowed it, the difference between legitimate 503A compounding pharmacies and unregulated sources, and how PlexusDx operates inside the legitimate pathway
Your GP may refer you to a specialist weight management service, an endocrinologist, or a hepatologist depending on your individual circumstances
If you or a loved one has been diagnosed with any of the following conditions after taking Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, Rybelsus, or Victoza, you may be eligible to file a legal claim against the drug manufacturers, Novo Nordisk and Eli Lilly: Gastroparesis Intestinal blockage Bowel obstruction Ileus Intestinal pseudo-blockage As the landscape of GLP-1 agonist litigation evolves, including potential future claims related to NAION, Cory Watson Attorneys remains committed to advocating for patient safety and holding pharmaceutical companies accountable for the harm their products may cause
